EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomized clinical trials
EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials – European Medicines Agency Related: FDA: Why you should not use Ivermectin to treat or prevent COVID-19 (statement, commentary, and RCT)
The post EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomized clinical trials appeared first on Links Medicus.
Mechanical ventilation parameters in critically ill COVID-19 patients: a scoping review
Mechanical ventilation parameters in critically ill COVID-19 patients: a scoping review – Critical Care
The post Mechanical ventilation parameters in critically ill COVID-19 patients: a scoping review appeared first on Links Medicus.
Guideline: SARS‐CoV‐2 infection, COVID‐19 and timing of elective surgery
SARS‐CoV‐2 infection, COVID‐19 and timing of elective surgery – Anaesthesia Related: Study from 116 countries suggests surgery should be delayed for at least seven weeks following a COVID-19 diagnosis to reduce mortality risk – Anaesthesia Commentary on Twitter Our research has underpinned key recommendations in new guidance on SARS-CoV-2 infection & elective surgery from […]
The post Guideline: SARS‐CoV‐2 infection, COVID‐19 and timing of elective surgery appeared first on Links Medicus.
[Press release – not published yet] AstraZeneca vaccine 79% effective for preventing symptomatic COVID-19
AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis – AstraZeneca Commentaries: AstraZeneca vaccine is 79% effective against symptomatic Covid-19, company says – CNN AND AstraZeneca’s Covid-19 vaccine shows better-than-expected efficacy in U.S. trial – STAT AND Expert reaction to press release from AstraZeneca announcing interim data on safety […]
The post [Press release – not published yet] AstraZeneca vaccine 79% effective for preventing symptomatic COVID-19 appeared first on Links Medicus.
Modeling Study: Vaccination alone is unlikely to contain COVID-19 infections in UK
Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study – The Lancet Infectious Diseases Commentaries: Risking further COVID-19 waves despite vaccination – The Lancet Infectious Diseases AND Vaccination alone is unlikely to contain COVID-19 infections in UK – The Lancet Commentary on Twitter Vaccination alone is unlikely to contain #COVID19 infections in UK, […]
The post Modeling Study: Vaccination alone is unlikely to contain COVID-19 infections in UK appeared first on Links Medicus.
Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review
Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review – Journal of the American College of Cardiologyv Commentary on Twitter @JACCJournals: We share a systematic summary of #anticcogulation,#antiplatelet, and #fibrinolysis #RCTs in #COVID19. Amazing work by @AzitaTalasaz and a stellar multidisciplinary team! Figs illustrate areas where we’ll have evidence, & the gaps. Link: https://t.co/t4ksxwjAze […]
The post Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review appeared first on Links Medicus.
Bioethics | “Europe’s Vaccine Ethics Call: Do No Harm and Let More Die?”
Europe’s Vaccine Ethics Call: Do No Harm and Let More Die? – The New York Times (free registration may be required) Related opinion: Covid-19 vaccine adverse events: balancing monitoring with confidence in vaccines – The BMJ Opinion See also: European Medicines Agency finds AstraZeneca vaccine is safe and benefits outweigh the risks (Statement and commentaries) […]
The post Bioethics | “Europe’s Vaccine Ethics Call: Do No Harm and Let More Die?” appeared first on Links Medicus.
B.1.351 strain of SARS-CoV-2 neutralization titer reduced 8- to 9-fold for Pfizer and AstraZeneca vaccinees. Convalescent plasma and therapeutic antibodies were less effective against this variant as well.
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera – Cell
The post B.1.351 strain of SARS-CoV-2 neutralization titer reduced 8- to 9-fold for Pfizer and AstraZeneca vaccinees. Convalescent plasma and therapeutic antibodies were less effective against this variant as well. appeared first on Links Medicus.
[Preprint] Oxford/AstraZeneca and Pfizer/BioNTech vaccines probably can still neutralize P.1 strain of SARS-CoV-2, but at lower levels
Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2 – bioRxiv Commentary: Existing COVID vaccines may protect against Brazilian variant – Oxford study – Reuters
The post [Preprint] Oxford/AstraZeneca and Pfizer/BioNTech vaccines probably can still neutralize P.1 strain of SARS-CoV-2, but at lower levels appeared first on Links Medicus.
SARS-CoV-2 variants B.1.351 and P.1 can escape from therapeutic antibodies and evade antibodies induced by infection or mRNA vaccination
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies – Cell
The post SARS-CoV-2 variants B.1.351 and P.1 can escape from therapeutic antibodies and evade antibodies induced by infection or mRNA vaccination appeared first on Links Medicus.